



HEALTH ALERT

FOR IMMEDIATE RELEASE May 28, 2021 CONTACT: (559) 514-4857

Health Alert: Bamlanivimab plus Etesevimab No Longer Recommended for Use in California for COVID-19

On May 26, 2021, given the sustained increase in the P.1 and B.1.351 variants, the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS) stopped the distribution of bamlanivimab plus etesevimab to California. The Centers for Disease Control and Prevention (CDC) has identified that the combined frequency of the P.1 variant and the B.1.351 variant now exceeds 10% in California. Results from in vitro assays that are used to assess the susceptibility of viral variants to particular monoclonal antibodies suggest that bamlanivimab and etesevimab administered together are not active against either the P.1 or B.1.351 variants.

The FDA recommends that health care providers in California instead use casirivimab plus imdevimab (i.e., REGEN-COV) therapy until further notice. Casirivimab plus imdevimab is an alternative monoclonal antibody therapy that is currently authorized for the same use as bamlanivimab plus etesevimab. Based on similar in vitro assay data currently available, casirivimab plus imdevimab is likely to retain activity against the P.1 and B.1.351 variants. All treatment sites can continue ordering casirivimab plus imdevimab from the authorized distributer using the direct ordering process.

Please see the <u>HHS/ASPR notice</u> regarding this update for more information.

Categories of Health Alert Messages:

Health Alert: Conveys the highest level of importance; warrants immediate action or attention

Health Advisory: Provides important information for a specific incident or situation; may not require immediate action

Health Update: Provides updated information regarding an incident or situation; unlikely to require immediate action

Health Information: Provides general health information which is not considered to be of emergent nature